Logo image of AUGX

AUGMEDIX INC (AUGX) Stock Fundamental Analysis

NASDAQ:AUGX - Nasdaq - US05105P1075 - Common Stock - Currency: USD

2.35  0 (0%)

After market: 2.35 0 (0%)

Fundamental Rating

2

AUGX gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 39 industry peers in the Health Care Technology industry. AUGX may be in some trouble as it scores bad on both profitability and health. AUGX is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

AUGX had negative earnings in the past year.
AUGX had a negative operating cash flow in the past year.
In the past 5 years AUGX always reported negative net income.
In the past 5 years AUGX always reported negative operating cash flow.
AUGX Yearly Net Income VS EBIT VS OCF VS FCFAUGX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 -5M -10M -15M -20M

1.2 Ratios

The Return On Assets of AUGX (-44.44%) is worse than 65.79% of its industry peers.
The Return On Equity of AUGX (-227.72%) is worse than 81.58% of its industry peers.
Industry RankSector Rank
ROA -44.44%
ROE -227.72%
ROIC N/A
ROA(3y)-44.98%
ROA(5y)-61.67%
ROE(3y)-606%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AUGX Yearly ROA, ROE, ROICAUGX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 0 -500 -1K -1.5K

1.3 Margins

AUGX's Gross Margin of 48.21% is on the low side compared to the rest of the industry. AUGX is outperformed by 60.53% of its industry peers.
In the last couple of years the Gross Margin of AUGX has grown nicely.
AUGX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 48.21%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y5.22%
GM growth 5Y45.73%
AUGX Yearly Profit, Operating, Gross MarginsAUGX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 0 -50 -100 -150 -200

More info and screens

2

2. Health

2.1 Basic Checks

AUGX does not have a ROIC to compare to the WACC, probably because it is not profitable.
AUGX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, AUGX has more shares outstanding
The debt/assets ratio for AUGX has been reduced compared to a year ago.
AUGX Yearly Shares OutstandingAUGX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
AUGX Yearly Total Debt VS Total AssetsAUGX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 20M 40M 60M

2.2 Solvency

AUGX has an Altman-Z score of -2.71. This is a bad value and indicates that AUGX is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of AUGX (-2.71) is worse than 65.79% of its industry peers.
A Debt/Equity ratio of 1.48 is on the high side and indicates that AUGX has dependencies on debt financing.
With a Debt to Equity ratio value of 1.48, AUGX is not doing good in the industry: 84.21% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 1.48
Debt/FCF N/A
Altman-Z -2.71
ROIC/WACCN/A
WACC9%
AUGX Yearly LT Debt VS Equity VS FCFAUGX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 10M -10M 20M -20M

2.3 Liquidity

AUGX has a Current Ratio of 1.66. This is a normal value and indicates that AUGX is financially healthy and should not expect problems in meeting its short term obligations.
AUGX's Current ratio of 1.66 is in line compared to the rest of the industry. AUGX outperforms 47.37% of its industry peers.
AUGX has a Quick Ratio of 1.66. This is a normal value and indicates that AUGX is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of AUGX (1.66) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 1.66
Quick Ratio 1.66
AUGX Yearly Current Assets VS Current LiabilitesAUGX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 15.66% over the past year.
Looking at the last year, AUGX shows a very strong growth in Revenue. The Revenue has grown by 39.34%.
AUGX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 32.90% yearly.
EPS 1Y (TTM)15.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-8.33%
Revenue 1Y (TTM)39.34%
Revenue growth 3Y39.62%
Revenue growth 5Y32.9%
Sales Q2Q%26.75%

3.2 Future

Based on estimates for the next years, AUGX will show a small growth in Earnings Per Share. The EPS will grow by 6.46% on average per year.
Based on estimates for the next years, AUGX will show a quite strong growth in Revenue. The Revenue will grow by 11.58% on average per year.
EPS Next Y-20.13%
EPS Next 2Y-3.76%
EPS Next 3Y6.46%
EPS Next 5YN/A
Revenue Next Year18.97%
Revenue Next 2Y22.71%
Revenue Next 3Y11.58%
Revenue Next 5YN/A

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
AUGX Yearly Revenue VS EstimatesAUGX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 20M 40M 60M
AUGX Yearly EPS VS EstimatesAUGX Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 -0.2 -0.4 -0.6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

AUGX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AUGX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AUGX Price Earnings VS Forward Price EarningsAUGX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AUGX Per share dataAUGX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.76%
EPS Next 3Y6.46%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AUGX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AUGMEDIX INC

NASDAQ:AUGX (10/1/2024, 8:00:01 PM)

After market: 2.35 0 (0%)

2.35

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)08-12 2024-08-12/amc
Earnings (Next)11-04 2024-11-04/bmo
Inst Owners72.68%
Inst Owner Change-99.26%
Ins Owners11.72%
Ins Owner Change-281.67%
Market Cap116.16M
Analysts80
Price Target3.6 (53.19%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)8.31%
Min EPS beat(2)4.41%
Max EPS beat(2)12.2%
EPS beat(4)4
Avg EPS beat(4)11.24%
Min EPS beat(4)4.41%
Max EPS beat(4)16.56%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-1.48%
Min Revenue beat(2)-1.76%
Max Revenue beat(2)-1.2%
Revenue beat(4)1
Avg Revenue beat(4)-0.56%
Min Revenue beat(4)-1.76%
Max Revenue beat(4)0.98%
Revenue beat(8)4
Avg Revenue beat(8)0.08%
Revenue beat(12)5
Avg Revenue beat(12)-0.26%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)1.29%
EPS NQ rev (1m)0%
EPS NQ rev (3m)5.74%
EPS NY rev (1m)0%
EPS NY rev (3m)1.85%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-4.06%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.64%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.25
P/FCF N/A
P/OCF N/A
P/B 11.09
P/tB 11.09
EV/EBITDA N/A
EPS(TTM)-0.44
EYN/A
EPS(NY)-0.48
Fwd EYN/A
FCF(TTM)-0.36
FCFYN/A
OCF(TTM)-0.31
OCFYN/A
SpS1.04
BVpS0.21
TBVpS0.21
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -44.44%
ROE -227.72%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 48.21%
FCFM N/A
ROA(3y)-44.98%
ROA(5y)-61.67%
ROE(3y)-606%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y5.22%
GM growth 5Y45.73%
F-Score5
Asset Turnover0.96
Health
Industry RankSector Rank
Debt/Equity 1.48
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 180.82%
Cap/Sales 4.95%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.66
Quick Ratio 1.66
Altman-Z -2.71
F-Score5
WACC9%
ROIC/WACCN/A
Cap/Depr(3y)178.38%
Cap/Depr(5y)139.24%
Cap/Sales(3y)4.74%
Cap/Sales(5y)4.8%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-8.33%
EPS Next Y-20.13%
EPS Next 2Y-3.76%
EPS Next 3Y6.46%
EPS Next 5YN/A
Revenue 1Y (TTM)39.34%
Revenue growth 3Y39.62%
Revenue growth 5Y32.9%
Sales Q2Q%26.75%
Revenue Next Year18.97%
Revenue Next 2Y22.71%
Revenue Next 3Y11.58%
Revenue Next 5YN/A
EBIT growth 1Y-14.13%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-19.28%
EBIT Next 3Y9.53%
EBIT Next 5YN/A
FCF growth 1Y12.92%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y21.91%
OCF growth 3YN/A
OCF growth 5YN/A